Study on the safety and efficacy of donor-specific transfusions in deceased-donor liver transplantation during COVID-19 outbreaks

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041375

Enrollment

Unknown

Registered

2020-12-24

Start date

2020-05-07

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage liver disease

Interventions

Experimental group:donor-specific transfusions

Control group:routine transfusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Meet the indications for liver transplantation, and sign the informed consent; 2.Aged 18-70 years; 3.Insufficient banked blood; 4.A negative cross-match; 5.Presence one of the following indications in the surgery: a) Hemoglobin of < 70g/L. b) Rapid intraoperative blood loss exceeded 1000mL. c) Intraoperative blood pressure instability was contemplated to be due to blood loss.

Exclusion criteria

Exclusion criteria: (1) Donors and family members refuse to donate blood; (2) Liver transplantation with incompatible blood type; (3) Positive irregular antibody test; (4) The length of ICU stay of the donor was > 7 days; (5) The donor has the clinical manifestation of infection or the diagnostic basis of infection; (6) Participants in other clinical trials at the same time.

Design outcomes

Primary

Measure	Time frame
Infection rates;Incidence of blood transfusion related complications;	—

Secondary

Measure	Time frame
liver function;incidence of complications;	—

Countries

China

Contacts

Public ContactJiayin Yang

West China Hospital of Sichuan University

docotoryjy@scu.edu.cn+86 18980602047

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026